Stalaris (efzofitimod) / aTyr Pharma, Kyorin 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stalaris (efzofitimod) / aTyr Pharma, Kyorin
NCT05415137 / 2022-001012-26: Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

Active, not recruiting
3
268
Europe, Japan, US, RoW
Efzofitimod 3 mg/kg, ATYR1923, KRP-R120, Efzofitimod 5 mg/kg, Placebo
aTyr Pharma, Inc., Kyorin Pharmaceutical Co.,Ltd
Pulmonary Sarcoidosis
07/25
09/25
aTyr Pharma_COVID: aTyr Pharma Announces Phase 2 Study of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications Following FDA Acceptance of IND Application

Recruiting
2
30
US
Stalaris (ATYR1923) - aTyr Pharma, Kyorin
aTyr Pharma
COVID-19
 
 
2018-004244-33: A safety study with multiple doses of intravenous (in the vein) ATYR1923 in patients with pulmonary sarcoidosis

Not yet recruiting
2
36
Europe
ATYR1923, ATYR1923, Solution for infusion
aTyr Pharma, Inc., aTyr Pharma, Inc.
Pulmonary Sarcoidosis, The disease is characterized by the buildup of immune system cells in organs that form small clusters called granulomas, a type of inflammation of the involved tissues., Diseases [C] - Respiratory Tract Diseases [C08]
 
 
SSc-ILD, NCT05892614: Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD)

Recruiting
2
25
US
efzofitimod 450 mg, efzofitimod 270 mg, Placebo
aTyr Pharma, Inc.
Interstitial Lung Disease
12/24
12/24

Download Options